Nevertheless, evaluating the sensitivity or resistance to target therapeutic populations according to stratification by cancer markers including TMB, PD-L1, tumor-infiltrating lymphocytes, and neoantigens can enhance the predictive efficacy of immunotherapeutic response [38]. This evidence concerns the gene CD274 and cancer.